Across TCGA pan-cancer cohorts, HLA-DRB5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HLA-DRB5 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher HLA-DRB5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HLA-DRB5 expression acts as an unfavorable survival marker.

PRAD are the cancer types where HLA-DRB5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: HLA-DRB5 tumor-vs-normal RNA expression · all HLA-DRB5 data types